Lipella Pharmaceuticals Announces Successful Phase 2a Study Results for LP-10 in Treating Oral Lichen Planus
I'm PortAI, I can summarize articles.
Lipella Pharmaceuticals Inc. has reported positive final results from its Phase 2a study of LP-10 for treating Oral Lichen Planus. The study, involving 27 patients, showed significant improvements across all efficacy endpoints with no serious adverse events. Mild to moderate treatment-related adverse events occurred in 18.5% of patients. Lipella plans to advance LP-10 into a pivotal Phase 2b study and is scaling manufacturing for larger trials while exploring strategic partnerships.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments